

Claims:

1. Immunogenic composition comprising a fusion protein and a saponin adjuvant, characterized in that the fusion protein comprises a heterologous hydrophobic peptide which is fused to the N-terminus and/or to the C-terminus of a core polypeptide, the core polypeptide comprising at least one protective epitope, the saponin adjuvant being in a free form.
2. Immunogenic composition according to claim 1, characterized in that the core polypeptide is a component of a protein of an organism of the phylum Apicomplexa.
3. Immunogenic composition according to claim 2, characterized in that the core polypeptide is a component of a protein of an organism of the Piroplasmida or of the class Coccidia.
4. Immunogenic composition according to claim 3, characterized in that the core polypeptide is a component of a protein of an organism of the genera *Eimeria* or *Babesia*.
5. Immunogenic composition according to any one of claims 1 to 4, characterized in that the heterologous hydrophobic peptide is from an N-terminal hydrophobic sequence.
6. Immunogenic composition according to any one of claims 1 to 4, characterized in that the heterologous hydrophobic peptide is from an internal hydrophobic sequence.
7. Immunogenic composition according to any one of claims 1 to 4, characterized in that the heterologous hydrophobic peptide is from a C-terminal hydrophobic sequence.
8. Immunogenic composition according to claim 7, characterized in that the C-terminal hydrophobic sequence is from decay accelerating factor (DAF).
9. Immunogenic composition according to any one of claims 1 to 8, characterized in that the saponin adjuvant is Quillaja saponin.

Best Available Copy

10. Vaccine characterized in that it comprises an immunogenic composition according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier.
11. Vaccine according to claim 10, characterized in that it comprises at least one additional immunoactive component.
12. Vaccine according to either one of claims 10 or 11, characterized in that it is in a freeze-dried form.
13. Method for the preparation of a vaccine according to claim 10, characterized in that the method comprises admixing an immunogenic composition according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier.
14. Use of an immunogenic composition according to any one of claims 1 to 9, for the manufacture of a vaccine.

Best Available Copy